Conference Correspondent

Dual Inhibition of Bruton’s Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias

Conference Correspondent - ASH 2018 - CLL

Genomics sequencing efforts have found a broad spectrum of mutations in many hematologic malignancies. Given the complex and heterogeneous nature of genetic subclones and the tumor microenvironment, it is likely that multiagent combinations with complementary mechanisms of action will be required to treat these diseases effectively over the disease continuum.

In this study, an ex vivo screening assay was used to identify small-molecule targeted inhibitors and inhibitor combinations demonstrating selective efficacy across broad categories of leukemia. Specimens isolated from 588 patients with leukemia were evaluated in the presence of a graded-concentration panel of more than 120 single-agent inhibitors or combinations spanning several different drug classes. Leukemia subgroups included acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia, and myeloproliferative neoplasms/myelodysplastic syndrome. The combinations selected for the analysis were designed as drug pairs that target different biological pathways and, therefore, have the potential to represent complementary mechanisms of action.

Statistical analyses revealed that the combination of venetoclax, a B-cell lymphoma 2 (BCL2) inhibitor, and ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, showed greater clinical benefit compared with either single agent in both myeloid and lymphoid malignancies, including AML, ALL, and CLL. When evaluating subgroups by mutational status in AML, researchers found that venetoclax + ibrutinib was particularly effective in patient samples with FLT3-ITD or NPM1 mutations.

These important preclinical findings demonstrated that both lymphoid- and acute myeloid–derived primary leukemia cells show sensitivity to combined inhibition of BCL2 and BTK with the combination of venetoclax and ibrutinib, suggesting this combination may have broad therapeutic indications.

Eide CA, et al. ASH 2018. Abstract 214.

Related Items
Prognostic Testing and Treatment Approaches in Patients with CLL: Interim Analysis of the informCLL Real-World Registry
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
Acalabrutinib in Patients with Relapsed/Refractory and High-Risk, Treatment-Naïve CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
Cost-Effectiveness Comparison of Ibrutinib, Chemotherapy, and Chemoimmunotherapy in First-Line Treatment of CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
ECOG-ACRIN Cancer Research Group: Phase 3 Study of Ibrutinib-Based Therapy in Untreated Younger Patients with CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
Ibrutinib Treatment in Waldenström’s Macroglobulinemia: Follow-Up Efficacy and Safety from the iNNOVATE Study
Conference Correspondent published on December 2, 2018 in ASH 2018 - CLL
Last modified: December 2, 2018
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME